制定超罕见风湿病指南:一段崎岖之路
本文从方法学视角描述了为自身炎症性疾病制定推荐意见过程中遇到的挑战,指出超罕见病领域熟悉疾病的医生少、文献稀缺,而常见病指南制定流程直接且基于医患经验与丰富文献。目标是寻找解决方案以促进未来超罕见病指南的制定。
要点
- 超罕见风湿病领域熟悉疾病的医生少且文献稀缺,与常见病指南制定所依赖的丰富文献和医患经验形成对比。
- 本文从方法学视角描述了为自身炎症性疾病制定推荐意见过程中出现的挑战。
- 目标是寻找解决方案以促进未来超罕见病指南的制定。
核心结论
- 本文描述了为自身炎症性疾病制定推荐意见过程中从方法学视角出现的挑战,目标是寻找解决方案以促进未来超罕见病指南的制定。
研究设计与样本
- 本文为观点类文章,从方法学视角描述为自身炎症性疾病制定推荐意见过程中出现的挑战。
主要发现
- 常见病指南制定流程直接,基于医患经验和丰富文献;超罕见病领域熟悉疾病的医生少且文献稀缺。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical practice guidelines are useful tools for both patients and physicians. Several standardised operating procedures are in existence to describe tasks step by step to develop guidelines/recommendations. The end product consists of data synthesis from the systematic literature search and patient/physician's inputs. For the prevalent diseases, the process for developing guidelines is straightforward; it is based on physicians'/patients' experiences and abundance of the literature. When it comes to the realm of ultrarare diseases, there are few physicians who are familiar with a disease, and there is a scarcity of literature. In this viewpoint, we describe challenges from the methodological perspectives that occurred during the process of developing recommendations for autoinflammatory disorders with the goal of finding solutions that facilitate the development of guidelines for ultrarare diseases in the future.
引用
- Piskin D, Romano M, Aletaha D, et al. Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Ann Rheum Dis. 2022. PMID: 35738880. doi:10.1136/ard-2022-222538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。